Karyopharm Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Karyopharm Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 13.7 times its market value (net debt). Lower than almost all Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$18For every $100 of sales, $18 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $31 tied up three years earlier.
Less money tied up than 62% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 7%
Sales fell 7% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-7% / -70%In 3 years sales changed by -7% while total assets changed by -70%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-3.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 61% of Healthcare companies in United States.
Cash Cushion Ratio
13.7× debtDebt, after subtracting cash, is 13.7 times its market value (net debt).
Lower than almost all Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Karyopharm Therapeutics Inc. made a loss over the last year. Karyopharm Therapeutics Inc. owes $3.97 for every $1 it owns. Karyopharm Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKaryopharm Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.04Karyopharm Therapeutics Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$12 MThe total market value of all of Karyopharm Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 86% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeKaryopharm Therapeutics Inc.'s net worth is negative ($330 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
3.97×Karyopharm Therapeutics Inc. owes $3.97 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Dividend yield
NoneKaryopharm Therapeutics Inc. does not currently pay a dividend.
Revenue growth
+1%Revenue rose 1% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Profit growth
LossKaryopharm Therapeutics Inc. made a loss in each of the last two years.
Profit margin
-134.2%Karyopharm Therapeutics Inc. lost $134 for every $100 of revenue.
Interest cover
Not coveredKaryopharm Therapeutics Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtKaryopharm Therapeutics Inc. had $170 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Karyopharm Therapeutics Inc. owe compared with what it owns?
Karyopharm Therapeutics Inc. owes $3.97 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Does Karyopharm Therapeutics Inc. pay a dividend?
No. Karyopharm Therapeutics Inc. does not currently pay a dividend.
Is Karyopharm Therapeutics Inc.'s revenue growing?
Revenue rose 1% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.